Last reviewed · How we verify

NCT05539404: FrameLP

Evaluate Endovascular Treatment of Large Ischemic Stroke With Substantial Penumbra.

Terminated NA Last updated 9 June 2023
What this trial tests

NA trial testing Endovascular treatment in addition of best medical treatment. in Acute Ischemic Stroke in 2 participants. Terminated before completion.

Timeline
2 November 2022
Primary endpoint
18 April 2023
18 April 2023

Quick facts

Lead sponsorUniversity Hospital, Toulouse
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment2
Start date2 November 2022
Primary completion18 April 2023
Estimated completion18 April 2023
Sites9 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Toulouse

Who can join

Adults 18 to 90, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Large cerebral infarctions are frequent and associated with a poor outcome. Previous cohort studies results suggest that patients with an acute ischemic stroke with large core and substantial penumbra on perfusion imaging benefit from EVT while those with no salvageable ischemic tissue did not. The Investigator aim to demonstrate in a randomized controlled trials (RCT) that EVT (Endo Vascular Treatment) in addition to BMT (Best Medical Treatment) increases the rate of functional recovery (mRS 0-2) at 3 months in patients with a LVO-related AIS with a large core and substantial penumbra evolving for less than 24hrs

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Ischemic Stroke

Currently open trials in the same condition.

Other University Hospital, Toulouse trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05539404.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing